Squarepoint’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,164,943
| Closed | -$9.62M | – | 5627 |
|
|
2024
Q4 | $9.62M | Buy |
3,164,943
+855,281
| +37% | +$3.73M | 0.01% | 1181 |
|
|
2024
Q3 | $12M | Buy |
+2,309,662
| New | +$11.5M | 0.02% | 860 |
|
|
2023
Q3 | – | Sell |
-32,206
| Closed | -$815K | – | 4348 |
|
|
2023
Q2 | $815K | Sell |
32,206
-57,023
| -64% | -$1.78M | ﹤0.01% | 2321 |
|
|
2023
Q1 | $2.87M | Buy |
89,229
+3,168
| +4% | +$98.8K | 0.01% | 1187 |
|
|
2022
Q4 | $1.59M | Buy |
86,061
+67,310
| +359% | +$1.54M | 0.01% | 1498 |
|
|
2022
Q3 | $506K | Sell |
18,751
-15,253
| -45% | -$309K | ﹤0.01% | 2201 |
|
|
2022
Q2 | $470K | Buy |
34,004
+357
| +1% | +$5.5K | ﹤0.01% | 2041 |
|
|
2022
Q1 | $656K | Buy |
+33,647
| New | +$510K | ﹤0.01% | 1855 |
|
|
2021
Q3 | – | Sell |
-30,463
| Closed | -$903K | – | 3546 |
|
|
2021
Q2 | $903K | Buy |
30,463
+20,396
| +203% | +$588K | ﹤0.01% | 1704 |
|
|
2021
Q1 | $281K | Buy |
+10,067
| New | +$278K | ﹤0.01% | 2459 |
|
|
2020
Q4 | – | Sell |
-23,946
| Closed | -$602K | – | 3334 |
|
|
2020
Q3 | $602K | Sell |
23,946
-34,423
| -59% | -$903K | 0.01% | 1294 |
|
|
2020
Q2 | $1.43M | Buy |
58,369
+29,103
| +99% | +$574K | 0.02% | 773 |
|
|
2020
Q1 | $433K | Sell |
29,266
-14,074
| -32% | -$291K | 0.01% | 1119 |
|
|
2019
Q4 | $703K | Buy |
+43,340
| New | +$672K | ﹤0.01% | 1558 |
|
|
2019
Q3 | – | Sell |
-67,528
| Closed | -$876K | – | 2740 |
|
|
2019
Q2 | $876K | Buy |
67,528
+40,082
| +146% | +$505K | 0.01% | 1336 |
|
|
2019
Q1 | $433K | Buy |
27,446
+14,799
| +117% | +$257K | ﹤0.01% | 1563 |
|
|
2018
Q4 | $255K | Sell |
12,647
-5,221
| -29% | -$115K | ﹤0.01% | 1573 |
|
|
2018
Q3 | $444K | Buy |
+17,868
| New | +$486K | 0.01% | 1355 |
|
|
2018
Q2 | – | Sell |
-17,130
| Closed | -$528K | – | 2111 |
|
|
2018
Q1 | $528K | Sell |
17,130
-15,061
| -47% | -$485K | 0.01% | 1074 |
|
|
2017
Q4 | $1.15M | Buy |
+32,191
| New | +$925K | 0.02% | 771 |
|
Other funds holding RVNC
Squarepoint's RVNC Position: Q1 2025 in Review
Squarepoint sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 3,164,943 shares — an estimated $9.62M sold.
Squarepoint first reported a position in RVNC in Q4 2017 and held it in 20 quarters. The position peaked at $12M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Squarepoint reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Squarepoint sold 3,164,943 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $9.62M.
- Squarepoint first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 20 quarters.
- Squarepoint's Revance Therapeutics, Inc. position peaked at $12M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.